logo
Global Big Pharma Partnering Terms and Agreements Analysis Report 2022: Trends in Dealmaking in the Biopharma Industry Since 2015 - ResearchAndMarkets.com

Global Big Pharma Partnering Terms and Agreements Analysis Report 2022: Trends in Dealmaking in the Biopharma Industry Since 2015 - ResearchAndMarkets.com

By AP News
Published - Oct 25, 2022, 05:18 AM ET
Last Updated - Jun 24, 2023, 01:38 AM EDT

DUBLIN--(BUSINESS WIRE)--Oct 25, 2022--

The "Global Big Pharma Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Big Pharma Partnering Terms and Agreements 2015-2022s report provides comprehensive access to available deals and contract documents for over 3,400 Big Pharma deals.

These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Big Pharma agreements announced in the life sciences since 2015.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 3,400 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Report scope

Big Pharma Partnering Terms and Agreements includes:

  • Trends in Big Pharma dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2015
  • Most active Big Pharma dealmakers since 2015

In Global Big Pharma Partnering Terms and Agreements 2015-2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

2.1. Introduction

2.2. Big Pharma partnering over the years

2.3. Most active Big Pharma dealmakers

2.4. Big Pharma partnering by deal type

2.5. Big Pharma partnering by therapy area

2.6. Big Pharma partnering by technology type

2.7. Deal terms for Big Pharma partnering

2.7.1 Big Pharma partnering headline values

2.7.2 Big Pharma deal upfront payments

2.7.3 Big Pharma deal milestone payments

2.7.4 Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

3.1. Introduction

3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

4.1. Introduction

4.2. Most active Big Pharma dealmakers

4.3. Most active Big Pharma partnering company profiles

Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

5.1. Introduction

5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Appendices

Appendix 1 - Big Pharma deals by company A-Z

Appendix 2 - Big Pharma deals by stage of development

Appendix 3 - Big Pharma deals by deal type

Appendix 4 - Big Pharma deals by therapy area

Appendix 5 - Deal type definitions

Appendix 6 - Further reading

For more information about this report visit https://www.researchandmarkets.com/r/qlabn8

View source version on businesswire.com:https://www.businesswire.com/news/home/20221025005526/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024